Literature DB >> 1796818

Epidemiological study of patients with systemic sclerosis in Tokyo.

T Tamaki1, S Mori, K Takehara.   

Abstract

We conducted an epidemiological study of systemic sclerosis in the city of Tokyo using the records of patients who had been registered to receive free medical service for intractable diseases. A total of 636 patients were registered as having systemic sclerosis in 1987, and we sent questionnaires to the doctor of each patient. The contents of the questionnaires included the patient's name, sex, age, occupation, major symptoms, therapy and laboratory findings. We received 357 completed replies, and were able to analyse them. Our study estimated that at 1 January 1988 the prevalence rate in Japan was between 2.1 and 5.3 per 100,000. The male/female ratio was 14:1. The ages of the patients when surveyed ranged from 17 to 82 years, with a mean age of 51 years, peaking with the most numerous group being 50-59 years. The characteristic signs of systemic sclerosis were as follows: proximal scleroderma, 75%; sclerodactyly, 91%; pitting scars, 49%; short sublingual frenulum, 49%; pulmonary fibrosis, 45%; diffuse pigmentation, 45%; and phalangeal contracture, 35%. Raynaud's phenomenon was present in 93% of patients, and was the initial symptom in 59% of cases. With respect to specific antinuclear antibodies, anticentromere antibody was present in 19% and antitopoisomerase I antibody was present in 27%.

Entities:  

Mesh:

Year:  1991        PMID: 1796818     DOI: 10.1007/BF00371817

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  11 in total

1.  Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma.

Authors:  L J McNeilage; U Youngchaiyud; S Whittingham
Journal:  Arthritis Rheum       Date:  1989-01

2.  Prevalence of scleroderma spectrum disorders in the general population of South Carolina.

Authors:  H R Maricq; M C Weinrich; J E Keil; E A Smith; F E Harper; A I Nussbaum; E C LeRoy; A R McGregor; F Diat; E J Rosal
Journal:  Arthritis Rheum       Date:  1989-08

3.  An epidemiological study of scleroderma in the West Midlands.

Authors:  A Silman; S Jannini; D Symmons; P Bacon
Journal:  Br J Rheumatol       Date:  1988-08

4.  Epidemiologic features of diffuse connective tissue disorders in Rochester, Minn., 1951 through 1967, with special reference to systemic lupus erythematosus.

Authors:  L T Kurland; W A Hauser; R H Ferguson; K E Holley
Journal:  Mayo Clin Proc       Date:  1969-09       Impact factor: 7.616

5.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

6.  Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979.

Authors:  C J Michet; C H McKenna; L R Elveback; R A Kaslow; L T Kurland
Journal:  Mayo Clin Proc       Date:  1985-02       Impact factor: 7.616

7.  The epidemiology of systemic sclerosis (scleroderma) among male U.S. veterans.

Authors:  T A Medsger; A T Masi
Journal:  J Chronic Dis       Date:  1978-02

8.  Epidemiology of systemic sclerosis (scleroderma).

Authors:  T A Medsger; A T Masi
Journal:  Ann Intern Med       Date:  1971-05       Impact factor: 25.391

9.  [Epidemiology of connective tissue diseases of the skin (scleroderma, dermatomyositis and polymyositis) in Japan].

Authors:  H Hatano
Journal:  Hautarzt       Date:  1982-07       Impact factor: 0.751

10.  Progressive systemic sclerosis in Auckland: a ten year review with emphasis on prognostic features.

Authors:  R J Eason; P L Tan; P J Gow
Journal:  Aust N Z J Med       Date:  1981-12
View more
  26 in total

Review 1.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 2.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

Review 3.  Systemic sclerosis: a world wide global analysis.

Authors:  Paola Coral-Alvarado; Aryce L Pardo; Natalia Castaño-Rodriguez; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Clin Rheumatol       Date:  2009-03-11       Impact factor: 2.980

Review 4.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

5.  Clinical features of scleroderma patients with contracture of phalanges.

Authors:  Ryuichi Ashida; Hironobu Ihn; Yoshihiro Mimura; Masatoshi Jinnin; Yoshihide Asano; Masahide Kubo; Kunihiko Tamaki
Journal:  Clin Rheumatol       Date:  2006-12-15       Impact factor: 2.980

Review 6.  Therapy for pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Curr Opin Rheumatol       Date:  2009-11       Impact factor: 5.006

7.  Unique clinical and autoantibody profile of a large Asian Indian cohort of scleroderma-do South Asians have a more aggressive disease?

Authors:  Ramya Janardana; Aswin M Nair; Ajit K Surin; John Anthony Jude Prakash; Mahasampath Gowri; Debashish Danda
Journal:  Clin Rheumatol       Date:  2019-07-15       Impact factor: 2.980

8.  Therapies for scleroderma-related pulmonary arterial hypertension.

Authors:  Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2009       Impact factor: 3.772

Review 9.  Scleroderma renal crisis: a rare but severe complication of systemic sclerosis.

Authors:  Luc Mouthon; Alice Bérezné; Guillaume Bussone; Laure-Hélène Noël; Peter M Villiger; Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 10.  Determinants of mortality in systemic sclerosis: a focused review.

Authors:  Dilli Ram Poudel; Divya Jayakumar; Abhijeet Danve; Shiv Tej Sehra; Chris T Derk
Journal:  Rheumatol Int       Date:  2017-11-07       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.